The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment

被引:148
作者
Ballestri, Stefano [1 ]
Nascimbeni, Fabio [2 ]
Romagnoli, Dante [2 ,3 ]
Lonardo, Amedeo [2 ,3 ]
机构
[1] Pavullo Hosp, Internal Med, Modena, Italy
[2] Azienda USL, NOCSAE, Internal Med, Modena, Italy
[3] Azienda USL, NOCSAE, Outpatient Liver Clin, Modena, Italy
关键词
fibrosis; HOMA-IR; inflammatory grading; iron; NAFLD; steatosis; FATTY LIVER-DISEASE; PATHOLOGICAL CRITERIA; FLIP ALGORITHM; DIABETIC MICE; SAF SCORE; FIBROSIS; NAFLD; ASSOCIATION; DIAGNOSIS; RISK;
D O I
10.1111/hepr.12656
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
AimThe diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently, more-than-mild portal inflammation has raised interest as a marker of NAFLD severity. We assessed the independent predictors of: (I) individual histological lesions of NASH; (II) diagnosis of NASH; (III) significant (stage 2) and advanced (stage 3) fibrosis; and (IV) more-than-mild portal inflammation. MethodsData from 118 consecutive biopsy-proven NAFLD patients observed at our institution were retrospectively analyzed. ResultsAt stepwise multivariate logistic regression analyses, independent predictors were as follows. For the individual histological features of NASH: insulin resistance (IR), assessed with Homeostasis Model Assessment-IR (HOMA-IR), serum uric acid (SUA) and serum total cholesterol (TCH) for moderate-to-severe steatosis; waist circumference (waist), HOMA-IR and TCH for lobular inflammation; waist, HOMA-IR, metabolic syndrome (MS), serum alanine aminotransferase (ALT), SUA and TCH for ballooning. For NASH diagnosis: waist, HOMA-IR, MS, ALT, SUA and TCH (Brunt etal.'s classification); ALT, SUA and TCH for NAS 5. For significant and advanced fibrosis, respectively: waist, MS and ALT; age, platelets, HOMA-IR, diabetes and TCH. For more-than-mild portal inflammation: serum aspartate aminotransferase (AST), serum iron, NAS 5 and significant liver fibrosis. ConclusionHOMA-IR, SUA, MS, ALT and TCH are independent predictors of NASH and its individual histological lesions, notably including fibrosis. Based on our findings, these factors should be considered major pathogenic drivers of NASH and, by inference, potential targets for treatment.
引用
收藏
页码:1074 / 1087
页数:14
相关论文
共 57 条
[1]
The Impact of Phlebotomy in Nonalcoholic Fatty Liver Disease: A Prospective, Randomized, Controlled Trial [J].
Adams, Leon A. ;
Crawford, Darrell H. ;
Stuart, Katherine ;
House, Michael J. ;
St Pierre, Timothy G. ;
Webb, Malcolm ;
Ching, Helena L. I. ;
Kava, Jenny ;
Bynevelt, Michael ;
MacQuillan, Gerry C. ;
Garas, George ;
Ayonrinde, Oyekoya T. ;
Mori, Trevor A. ;
Croft, Kevin D. ;
Niu, Xianwa ;
Jeffrey, Gary P. ;
Olynyk, John K. .
HEPATOLOGY, 2015, 61 (05) :1555-1564
[2]
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[3]
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease [J].
Angulo, Paul ;
Kleiner, David E. ;
Dam-Larsen, Sanne ;
Adams, Leon A. ;
Bjornsson, Einar S. ;
Charatcharoenwitthaya, Phunchai ;
Mills, Peter R. ;
Keach, Jill C. ;
Lafferty, Heather D. ;
Stahler, Alisha ;
Haflidadottir, Svanhildur ;
Bendtsen, Flemming .
GASTROENTEROLOGY, 2015, 149 (02) :389-+
[4]
[Anonymous], DIABETES CARE S1
[5]
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease [J].
Ballestri, Stefano ;
Lonardo, Amedeo ;
Bonapace, Stefano ;
Byrne, Christopher D. ;
Loria, Paola ;
Targher, Giovanni .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (07) :1724-1745
[6]
Nonalcoholic Fatty Liver Disease Activity Score and Brunt's Pathologic Criteria for the Diagnosis of Nonalcoholic Steatohepatitis: What Do They Mean and Do They Agree? [J].
Ballestri, Stefano ;
Lonardo, Amedeo ;
Loria, Paola .
HEPATOLOGY, 2011, 53 (06) :2142-2143
[7]
Impact of fatty liver disease on health care utilization and costs in a general population:: A 5-year observation [J].
Baumeister, Sebastian E. ;
Voelzke, Henry ;
Marschall, Paul ;
John, Ulrich ;
Schmidt, Carsten-Oliver ;
Flessa, Steffen ;
Alte, Dietrich .
GASTROENTEROLOGY, 2008, 134 (01) :85-94
[8]
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD [J].
Bazick, Jessica ;
Donithan, Michele ;
Neuschwander-Tetri, Brent A. ;
Kleiner, David ;
Brunt, Elizabeth M. ;
Wilson, Laura ;
Doo, Ed ;
Lavine, Joel ;
Tonascia, James ;
Loomba, Rohit .
DIABETES CARE, 2015, 38 (07) :1347-1355
[9]
Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease [J].
Beaton, M. D. ;
Chakrabarti, S. ;
Levstik, M. ;
Speechley, M. ;
Marotta, P. ;
Adams, P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (07) :720-729
[10]
Utility and Appropriateness of the Fatty Liver Inhibition of Progression (FLIP) Algorithm and Steatosis, Activity, and Fibrosis (SAF) Score in the Evaluation of Biopsies of Nonalcoholic Fatty Liver Disease [J].
Bedossa, Pierre .
HEPATOLOGY, 2014, 60 (02) :565-575